Press release
Gout Pipeline Outlook 2025: Insights Into Therapies, Research, and Market Potential
Download DelveInsight's comprehensive Gout Pipeline Report to explore emerging therapies, key players, and future treatment landscapes @ Gout Pipeline Outlook Report [https://www.delveinsight.com/sample-request/gouty-arthritis-gout-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Gout Pipeline Report
* On 28 August 2025, Crystalys Therapeutics announced a study is to evaluate the efficacy of dotinurad in lowering serum uric acid (sUA) at Week 24 compared with allopurinol in adult participants with hyperuricemia associated with gout.
* On 26 August 2025, Amgen conducted a study consists of 24-week double-blind trial to evaluate the non-inferiority of the efficacy and safety of pegloticase Q4W with MTX versus pegloticase Q2W with MTX, followed by a 24-week open-label extension of pegloticase Q4W with MTX, in participants with uncontrolled refractory gout.
* DelveInsight's Gout pipeline report depicts a robust space with 25+ active players working to develop 30+ pipeline therapies for Gout treatment.
* The leading Gout Companies such as Jiangsu Atom Bioscience and Pharmaceutical, LG Chem, Shanton Pharma, TWi Biotechnology, Olatec Therapeutics, JW Pharmaceutical, Revive Therapeutics, Hinova Pharmaceuticals, Arthrosi Therapeutics, Dyve Biosciences, Swedish Orphan Biovitrum, Allen Pharmaceuticals, Teijin Pharma, AstraZeneca, R-Pharm, InventisBio, Sinovent, Shenyang Sunshine Pharmaceutical and others.
* Promising Gout Pipeline Therapies such as Pegloticase, Methotrexate, Epaminurad 6 mg, ABP-671, Allopurinol, D-0120, Dotinurad, Febuxostat and others.
Access DelveInsight's in-depth Gout Pipeline Analysis for a closer look at promising breakthroughs @ Gout Clinical Trials and Studies [https://www.delveinsight.com/sample-request/gouty-arthritis-gout-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
The Gout Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Gout Pipeline Report also highlights the unmet needs with respect to Gout.
Gout Overview
Gout, historically referred to as the ""disease of kings and king of diseases,"" is one of the most common causes of chronic inflammatory arthritis, particularly in the United States. It is defined by the deposition of monosodium urate crystals in joints and surrounding tissues, driven by hyperuricemia-serum urate levels exceeding 6.8 mg/dL, the solubility threshold of urate in blood. Clinically, gout can present as acute inflammatory arthritis flares, chronic joint damage (gouty arthropathy), tophaceous deposits, uric acid kidney stones, and chronic kidney disease. Despite its long-recognized history, gout remains a well-studied and manageable condition.
Gout Emerging Drugs Profile
* LC350189: LG Chem
Tigulixostat (LC350189) is a novel xanthine oxidase inhibitor targeting the reduction of uric acid in purine metabolism, by inhibiting the activity of xanthine oxidase. It has a different structure from other xanthine oxidase inhibitors such as the purine analog xanthine oxidase inhibitor, allopurinol. Tigulixostat is under development as a first line treatment in the US and has demonstrated sufficient efficacy for sUA lowering and a good safety profile in a Phase II study. Currently, the drug is in the Phase III stage of its development for the treatment of Gout.
* SAP-001: Shanton Pharma
SAP-001 is an investigational drug developed by Shanton Pharma, specifically designed to treat refractory and tophaceous gout, a severe form of the condition that often does not respond to standard treatments. This drug functions as a urate transporter inhibitor, targeting the uric acid transporter 1 (URAT1) to lower urate levels in patients who have not adequately responded to traditional therapies like allopurinol or febuxostat. Currently, the drug is in the Phase II stage of its development for the treatment of Gout.
* D-0120: InventisBio
D-0120 is a novel oral selective uric acid transporter (URAT1) inhibitor being developed for the treatment of gout by blocking the reabsorption of uric acid (UA) within the renal proximal tubule, thereby reducing serum uric acid concentrations. As a novel URAT1 inhibitor, D-0120 is anticipated to have more potent serum UA reducing effect than the approved URAT1 inhibitor lesinurad, but with less toxicity and wider therapeutic window. The pharmacological potential of D-0120 for the treatment of hyperuricemia and gout was demonstrated in preclinical studies. The results of the in vitro hURAT1 expressed CHO cell model showed that the inhibitory activity of D-0120 is 150-fold more potent than lesinurad and slightly more potent than verinurad. A Phase I clinical trial for D-0120 has been completed in the US, and good efficacy and excellent safety profile have been observed. Currently, the drug is in the Phase II stage of its development for the treatment of Gout.
* ABP-745: Jiangsu Atom Bioscience and Pharmaceutical
ABP-745 is an emerging small molecule drug developed by Atom Bioscience, primarily targeting the treatment of acute gout. While specific mechanisms are not fully detailed, ABP-745 is noted for its anti-inflammatory properties and is designed to be orally administered. According to the company's pipeline, currently the drug is in the Phase II stage of its development for the treatment of Gout.
The Gout Pipeline Report Provides Insights into
* The report provides detailed insights about companies that are developing therapies for the treatment of Gout with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Gout Treatment.
* Gout Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Gout Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Gout market
Explore groundbreaking therapies and clinical trials in the Gout Pipeline. Access DelveInsight's detailed report now! @ New Gout Drugs [https://www.delveinsight.com/sample-request/gouty-arthritis-gout-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Gout Companies
Jiangsu Atom Bioscience and Pharmaceutical, LG Chem, Shanton Pharma, TWi Biotechnology, Olatec Therapeutics, JW Pharmaceutical, Revive Therapeutics, Hinova Pharmaceuticals, Arthrosi Therapeutics, Dyve Biosciences, Swedish Orphan Biovitrum, Allen Pharmaceuticals, Teijin Pharma, AstraZeneca, R-Pharm, InventisBio, Sinovent, Shenyang Sunshine Pharmaceutical and others.
Gout Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
* Intravenous
* Oral
* Parenteral
* Subcutaneous
* Topical
Gout Products have been categorized under various Molecule types such as
* Protein
* Small interfering RNA
* Small molecule
Download DelveInsight's latest report to gain strategic insights into upcoming therapies and key developments @ Gout Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/gouty-arthritis-gout-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Gout Pipeline Report
* Coverage- Global
* Gout Companies- Jiangsu Atom Bioscience and Pharmaceutical, LG Chem, Shanton Pharma, TWi Biotechnology, Olatec Therapeutics, JW Pharmaceutical, Revive Therapeutics, Hinova Pharmaceuticals, Arthrosi Therapeutics, Dyve Biosciences, Swedish Orphan Biovitrum, Allen Pharmaceuticals, Teijin Pharma, AstraZeneca, R-Pharm, InventisBio, Sinovent, Shenyang Sunshine Pharmaceutical and others.
* Gout Pipeline Therapies- Pegloticase, Methotrexate, Epaminurad 6 mg, ABP-671, Allopurinol, D-0120, Dotinurad, Febuxostat and others.
* Gout Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Gout Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Which companies are leading the race in Gout drug development? Find out in DelveInsight's exclusive Gout Pipeline Report-access it now! @ Gout Emerging Drugs and Major Companies [https://www.delveinsight.com/sample-request/gouty-arthritis-gout-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Contents
* Introduction
* Executive Summary
* Gout: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Gout- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* LC350189: LG Chem
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* SAP-001: Shanton Pharma
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* Drug Name: Company Name
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug Name: Company Name
* Drug profiles in the detailed report.....
* Inactive Products
* Gout Key Companies
* Gout Key Products
* Gout- Unmet Needs
* Gout- Market Drivers and Barriers
* Gout- Future Perspectives and Conclusion
* Gout Analyst Views
* Gout Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=gout-pipeline-outlook-2025-insights-into-therapies-research-and-market-potential]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/gouty-arthritis-gout-pipeline-insight
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Gout Pipeline Outlook 2025: Insights Into Therapies, Research, and Market Potential here
News-ID: 4174550 • Views: …
More Releases from ABNewswire
SMARTCOBY ULTRA SLIM 3K Redefines Portable Power: Just 4.98mm Thin with Apple-Tr …
CIO Inc. announces the launch of the SMARTCOBY ULTRA SLIM 3K, the world's thinnest 4.98mm mobile power bank. Featuring premium ATL battery cells trusted by Apple, a reinforced stainless-steel frame, and Apple-certified Find My integration, it delivers unmatched safety, convenience, and portability. With MagSafe compatibility and USB-C fast charging, it redefines what a power bank can be-ultra-thin, ultra-strong, and always reliable.
Osaka, Japan - September 30, 2025 - CIO Inc. today…
Fortress Expands Service Portfolio with Cutting-Edge Generative Engine Optimizat …
Leading SEO Agency Introduces GEO Services to Help Clients Dominate AI-Powered Search Results
FLORIDA - September 30, 2025 - Fortress [https://fortressgrowth.com], a leading provider of generative engine optimization (GEO) services, today announced the launch of its comprehensive GEO solutions designed to help businesses optimize their content for AI-powered search engines and generative platforms. This strategic expansion reinforces Fortress's commitment to staying ahead of the evolving digital landscape.
Pioneering the Future of Search…
Transform Interiors with Stylish and Functional Wall Paneling
Investing in wall paneling is an effective way to transform interiors, offering protection, functionality, and a modern design statement. With options suitable for a variety of styles and settings, wall panels provide homeowners and businesses with a practical and stylish solution to elevate their spaces.
Wall paneling has emerged as a versatile and stylish solution for homeowners and interior designers looking to enhance the aesthetics and functionality of living and commercial…
Enhance Home Interiors with Quality Skirting Boards
For those looking to upgrade their interiors, investing in quality skirting boards is a simple yet effective way to transform a room. From protecting walls to enhancing aesthetics, skirting boards play a crucial role in creating polished, sophisticated, and functional living spaces.
In modern interior design, small details can make a significant impact on the overall look and feel of a home. One such detail that combines functionality and aesthetic appeal…
More Releases for Gout
Chronic Gout Market Trends, Therapeutics, and Growth Opportunities
Chronic gout is a progressive form of arthritis characterized by elevated uric acid levels, leading to severe joint pain, inflammation, and long-term joint damage. This condition affects millions worldwide, often resulting in impaired mobility and reduced quality of life. With rising prevalence due to lifestyle changes, aging populations, and dietary habits, the Chronic Gout market is witnessing a surge in demand for advanced therapeutics, early diagnostics, and patient management solutions.
Download…
Chronic Gout Market Massive Growth opportunity Ahead
Introduction
Chronic gout is a form of arthritis characterized by recurrent attacks of severe pain, swelling, and inflammation in the joints, often due to the accumulation of uric acid crystals. This condition typically affects the big toe but can also impact other joints, including the knees, elbows, and wrists. Uric acid, a by-product of purine metabolism, accumulates in the body due to overproduction or underexcretion by the kidneys, leading to hyperuricemia…
Gout Market Innovations in Pain Management and Treatment
On April 08, 2025, Exactitude Consultancy., Ltd. announces the release of the report "Global Gout Market 2025 by Manufacturers, Regions, Type and Application, Forecast to 2034". The report is a detailed and comprehensive analysis presented by region and country, type and application. As the market is constantly changing, the report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many…
Gout Therapeutics Market Analysis By Drug Class (Nonsteroidal Anti-inflammatory …
Report Summary
The global gout therapeutics market was valued at USD 2.78 Billion in 2021 and is expected to grow at a CAGR of 13.7% during the forecast period 2023-2032.
Gout Therapeutics Market Introduction
The deposition of monosodium crystals (MSU) into the distal joints and peripheral tissues results in gout, an inflammatory arthritic disease. Gout is a typical type of painful inflammatory arthritis. One joint is typically affected at a time (often…
Global Gout Drugs Market Analysis (2020-2025)
Global Info Research offers a latest published report on Gout Drugs Analysis and Forecast 2020-2025 delivering key insights and providing a competitive advantage to clients through a detailed report. This report focuses on the key global Gout Drugs Concentrate players, to define, describe and analyze the value, market share, market competition landscape, SWOT analysis and development plans in next few years.
Click to view the full report TOC, figure and tables:
https://www.globalinforesearch.com/reports/371311/gout-drugs
Market…
Gout Therapeutics Market Emerging Trends And Forecast By 2025
Global Gout Therapeutics Market: Snapshot
The objective of treatment during a severe gout attack involves suppressing inflammation and controlling pain. The treatment of inflammation and pain can be attained with non-steroidal anti-inflammatory drugs, colchicine, or corticosteroids. The line of treatment chosen that would be suitable depends on the co-morbid medical conditions of the patient, side effect profile, and other medications.
Patients with multiple episodes of severe gout attacks every year or with…
